Prognostic factors in patients with pathological stage I non-seminomatous testicular germ cell tumors and tumor recurrence during follow-up

P. Albers, W. T. DeRiese, T. M. Ulbright, J. P. Donohue, R. S. Foster

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Clinical staging in patients with stage I nonseminomatous germ cell tumors (NSGCTs) of the testis fails in 30% to correctly assess pathological stage since microscopic and small-volume retroperitoneal disease is not detectable on computed tomography of the abdomen. Patients staged by retroperitoneal lymph node dissection as pathological stage I incur a distant (chest or serological) tumor relapse rate of 7-15% during follow-up. Recently, we reported on new risk factors as predictors of pathological stage by flow cytometric DNA analysis in clinical stage I patients. These same methods were applied to a group of 14 pathological stage I patients who subsequently had either chest or serological recurrence. The findings in this group of patients were compared with those in a group of 47 pathological stage I patients who did not experience recurrence. In pathological stage I NSGCT patients with distant (chest or serological) tumor relapse, we found by histological evaluation and DNA analysis of the original orchiectomy specimen proliferative tumor activity to be significantly predictive of relapse. Much as proliferative activity of the primary tumor is predictive of retroperitoneal metastasis, it may be a predictor of recurrence in pathological stage I patients.

Original languageEnglish (US)
Pages (from-to)211-213
Number of pages3
JournalUrological Research
Volume23
Issue number4
DOIs
StatePublished - Aug 1 1995

Keywords

  • Flow cytometry
  • Non-seminomatous testicular germ cell tumors
  • Prognostic parameters
  • Tumor recurrence

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Prognostic factors in patients with pathological stage I non-seminomatous testicular germ cell tumors and tumor recurrence during follow-up'. Together they form a unique fingerprint.

  • Cite this